** Shares of vaccine maker Novavax NVAX.O rise 13% to $7.06 premarket

** Co says its COVID-19 vaccine is "approvable based on conversations with the U.S. Food and Drug Administration (FDA)"

** NVAX also says it has received a request from the FDA for a commitment to provide additional clinical data on its vaccine if it secures an approval

** The FDA had missed its deadline for making a decision on traditional approval for co's protein-based shot earlier this month

** Up to last close, stock had fallen 22.3% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))